Stonebrook Private Inc. Invests $228,000 in Danaher Co. (NYSE:DHR)

Stonebrook Private Inc. purchased a new position in Danaher Co. (NYSE:DHR) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 819 shares of the conglomerate’s stock, valued at approximately $228,000.

Other institutional investors have also recently bought and sold shares of the company. Montrusco Bolton Investments Inc. raised its holdings in shares of Danaher by 30.4% during the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after acquiring an additional 397,671 shares during the period. Nwam LLC acquired a new stake in Danaher during the 3rd quarter valued at $3,661,000. Studio Investment Management LLC lifted its holdings in shares of Danaher by 4.2% in the third quarter. Studio Investment Management LLC now owns 1,449 shares of the conglomerate’s stock valued at $403,000 after purchasing an additional 59 shares in the last quarter. Allen Capital Group LLC boosted its position in shares of Danaher by 24.3% in the third quarter. Allen Capital Group LLC now owns 1,519 shares of the conglomerate’s stock worth $422,000 after buying an additional 297 shares during the period. Finally, AlphaCore Capital LLC grew its holdings in shares of Danaher by 18.9% during the third quarter. AlphaCore Capital LLC now owns 3,895 shares of the conglomerate’s stock valued at $1,084,000 after buying an additional 619 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $235.84 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a one year low of $215.68 and a one year high of $281.70. The company’s fifty day moving average price is $258.15 and its 200 day moving average price is $259.95. The company has a market capitalization of $170.34 billion, a PE ratio of 45.01, a price-to-earnings-growth ratio of 4.32 and a beta of 0.85.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.02 EPS. As a group, analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.

Analyst Ratings Changes

A number of brokerages have commented on DHR. UBS Group decreased their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. TD Cowen increased their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Monday, November 18th. Finally, Barclays cut their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $287.16.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.